Filing Details
- Accession Number:
- 0001140859-24-000095
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-31 16:00:45
- Reporting Period:
- 2024-03-18
- Accepted Time:
- 2024-05-31 16:00:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1140859 | Cencora Inc. | COR | Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122) | 233079390 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1625811 | Gina Clark | 1 West First Avenue Conshohocken PA 19428 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-03-18 | 9,644 | $238.12 | 15,158 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-05-29 | 27,093 | $86.09 | 42,251 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-05-29 | 27,093 | $216.07 | 15,158 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2024-05-29 | 27,093 | $0.00 | 27,093 | $86.09 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2026-11-13 | No | 4 | M | Direct |
Footnotes
- Sale pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person effective 12/14/2023.
- The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $216.00 to $216.14, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- Exercisable in four equal installments on 11/13/20, 11/13/21, 11/13/22 and 11/13/23.